Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
2024年2月23日 - 3:02AM
Sanofi’s Board of Directors proposes the appointment of Clotilde
Delbos, Anne-Françoise Nesmes and John Sundy as independent
Directors
Paris, February 22, 2024. At
its meeting on February 22, 2024, Sanofi’s Board of Directors has
decided to propose, on the occasion of its next General Shareholder
Meeting to be held on April 30, 2024, the renewal of the terms of
office of Rachel Duan and Lise Kingo and the appointment of
Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as
independent Directors. Diane Souza, Member of the Audit and
Compensation Committees, and Thomas Südhof, Chairman of the
Scientific Committee, will leave the Board of Directors at the end
of their second terms. The Chairman warmly thanked them for their
valued contribution to the Board of Directors and the specialized
committees to which they belonged during their terms in office.
The Chairman specified that, in order to prepare
as effectively as possible for the end, in 2025, of the term of
office as director of Fabienne Lecorvaisier, Chairman of the Audit
Committee, the Board of Directors will temporarily comprise 17
members as from the General Shareholder Meeting of April 30,
2024.
Clotilde Delbos is currently
director of Axa and Alstom. She held various positions in internal
audit, merger and acquisitions and treasury, in California,
Brussels and France, notably at Price Waterhouse and the Pechiney
group, before becoming Division Chief Financial Officer. In 2012,
she joined the Renault Group. In 2016, Clotilde Delbos was
appointed Group Chief Financial Officer and Chairman of Board of
Directors of RCI Banque. She was then appointed Interim Chief
Executive Officer of Renault SA, Deputy Chief Executive Officer of
the group and Chief Executive Officer of Mobilize. Clotilde Delbos
was awarded the Légion d’Honneur in 2021.
Clotilde Delbos graduated from EM Lyon with a
specialization in accounting.
Anne-Françoise Nesmes is
currently Chief Financial Officer of Smith + Nephew PLC, a role
from which she will step down at the end of the first quarter of
2024. She joined the Board of Compass Group PLC as a non-executive
director in 2018 and currently serves as Senior Independent
Director, Chair of the Audit Committee and a member of the
Corporate Responsibility, Nomination and Remuneration Committees.
She held a number of finance positions in international companies
before joining GlaxoSmithKline PLC in 1997, where she worked for 16
years, including as Senior Vice President of Finance for global
vaccines. She then became Chief Financial Officer of Dechra
Pharmaceuticals PLC and Merlin Entertainments PLC
(2013-2020).Anne-Françoise Nesmes holds a Master’s degree from
Grenoble Business School and a Master’s degree in Business
Administration from Henley Management College. She is also a
Chartered Management Accountant.
John Sundy is currently Chief
Medical Officer and Head of Research and Development at Seicmic
Therapeutic, a machine learning immunology company and is Adjunct
Professor of Medicine in the Division of Rheumatology and
Immunology at Duke University School of Medicine. He was a tenured
faculy member at Duke University before moving to the biotech
industry in 2014. Between 2014 and 2021, he held several management
positions including Senior Vice President at Gilead Sciences, and
Chief Medical Officer at Pandion Therapeutics.He is also a director
of Neutrolis, Inc, and the Childhood Arthritis and Rheumatology
Research Alliance, and serves on the Steering Committee of the NIH
Immune Tolerance Network.John Sundy obtained a B.S. in biology from
Bucknell University and an M.D./Ph.D from Hahnemann University with
a specialization in immunology, and completed clinical training in
rheumatology and allergy/immunology at Duke.
Frédéric OudéaChairman of the
Board of Directors“The arrivals of Clotilde Delbos, Anne-Françoise
Nesmes and John Sundy will strengthen the Board of Directors’
expertise in finance and science, notably in the field of
immunology. I would like to pay tribute to the remarkable
contribution of Diane Souza and Thomas Südhof to the work of the
Board, and I am delighted that the Board continues to diversify its
profiles and competencies, in line with the Group’s strategic
developments.”
The composition of the Board’s specialized
committees will be reviewed following the Annual General Meeting of
Shareholders scheduled for April 30, 2024.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi (EU:SAN)
過去 株価チャート
から 3 2024 まで 4 2024
Sanofi (EU:SAN)
過去 株価チャート
から 4 2023 まで 4 2024